| For: | Arriola-Montenegro J, Beas R, Cerna-Viacava R, Chaponan-Lavalle A, Hernandez Randich K, Chambergo-Michilot D, Flores Sanga H, Mutirangura P. Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease. World J Cardiol 2023; 15(7): 328-341 [PMID: 37576545 DOI: 10.4330/wjc.v15.i7.328] |
|---|---|
| URL: | https://www.wjgnet.com/2150-5349/full/v15/i7/328.htm |
| Number | Citing Articles |
| 1 |
Yusuke Hirao, Clarke Morihara, Tomoki Sempokuya. Kill two birds with one stone: Hapatologist’s approach to metabolic dysfunction-associated steatotic liver disease and heart failure. World Journal of Cardiology 2024; 16(11): 660-664 doi: 10.4330/wjc.v16.i11.660
|
| 2 |
Morag J. Young, Peter J. Fuller, Onno C. Meijer, Timothy J. Cole, Monica Kanki, Jun Yang, Quoc Viet Ho, Nikshay Karthigan, Seamus Heanue. Regulation of the Mineralocorticoid Receptor in Physiology and Disease. Pharmacological Reviews 2026; doi: 10.1016/j.pharmr.2026.100156
|
| 3 |
Darshan Hullon, Ghasaq K. Subeh, Yelizaveta Volkova, Karolina Janiec, Adam Trach, Ruslan Mnevets. The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF). Cardiovascular Diabetology 2025; 24(1) doi: 10.1186/s12933-025-02607-w
|
| 4 |
Daifei Shen, Runji Chen, Shu Ye. Link between Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Diseases. Research 2026; 9 doi: 10.34133/research.1373
|
| 5 |
Diana Carina Iovanovici, Bombonica Gabriela Dogaru, Carmen Delia Nistor – Cseppento, Anamaria Lavinia Purza, Cristina Aur, Diana Mocuta, Tapan Behl, Simona Gabriela Bungau. Benefits of sacubitril/valsartan administration and physical training in cardiac rehabilitation: current trends and bibliometric analysis of the years 2015-2024. Balneo and PRM Research Journal 2024; 15(Vol.15, no. 2) doi: 10.12680/balneo.2024.683
|